Navigation Links
Vermillion Announces First Quarter 2008 Financial Results and Business Progress
Date:5/15/2008

10 reverse stock split of the Company's common stock, which became

effective at the close of trading on March 3, 2008.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.

Forward Looking Statements -- This news release contains forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. There are no guarantees that Vermillion will succeed in its efforts to commercialize PAD, ovarian cancer or hematology diagnostics products in 2008 or during any other period of time. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty in obtaining intellectual property protection for inventions made by Vermillion; (2) unproven ability of Vermillion to discover, develop, and commercialize PAD, ovarian cancer or hematology diagnostic products based on findings from its disease association studies; (3) unproven ability of Vermillion to discover or identify
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2008)...FirstCall/ -- Eli Lilly and,Company (NYSE: LLY ) ...ion,of SGX Pharmaceuticals, Inc. (Nasdaq: SGXP ),...n drug discovery and development in the area,of on...s Special,Stockholders Meeting, in which a majorit... agreement with Lilly. Under the agreement, Lilly ...
(Date:8/20/2008)... and Caregivers, Grassroots ...ewswire-USNewswire/ -- Inc. Magazine has,named Sen...an for,low-income seniors, the number one fastest-...rt of Inc.,s annual list of the country,s 500 fast...1,000 percent from 2004 to 2007., "This is a rewa...
(Date:8/20/2008)...ll/ -- CEL-SCI CORPORATION,(Amex: CVM ) reports f...ing,June 30, 2008., The Company,s loss from opera...76,679 versus a loss of $3,776,263 during the same...ns for the nine months ended June 30, 2008,was $7,...e nine months in,2007., The net loss per common s...
(Date:8/20/2008).../ -- Huifeng Bio-Pharmaceutical,Technology, Inc (O...producer of plant extracts and pharmaceutical raw ... and food production, today announced it will,be i... August 19-21 in Rio,de Janeiro, Brazil., "Unpara...volved in the,pharmaceutical raw materials industr...
Breaking Biology Technology:Lilly Announces Completion of SGX Acquisition 2Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US 2Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US 3CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 2CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 3CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 4CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 5Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil 2
...ot too early to gauge the level of investor intere...pany formed by Beth Donley and University of Wisc... , ,Donley already is rubbing elbows with interest...hat one of the key criteria for eventually attract...occupying a unique market position. , ,As she deve...
...zer spent about $800 million to develop torcetrap...til people began to die in clinical trials. Hours ...he company called a halt to further trials, a deci...s of jobs in jeopardy. , ,The drama surrounding Pf...s facing America,s pharmaceutical industry, but it...
...amirez has little need for market research, especi... ,When your user base is part of the creative clas... MorphVOX - can turn a soft voice into a baritone,...tor hadn,t considered. , ,Ramirez, CEO of Screami...,000 consumers that have ordered the company,s voi...
...attempt to measurably increase the amount of capit...partment of Financial Institutions and the Depar...a Venture Capital Center. , ,Lorrie Keating Heinem...courage institutional investors to place a percent...ners in regional venture capital firms, or invest ...
Other Biology Technology:UW scientist, former WiCell director found stem cell company 2UW scientist, former WiCell director found stem cell company 3Failure of heart drug offers lessons for drug industry 2Failure of heart drug offers lessons for drug industry 3Users help software company morph in new directions 2Users help software company morph in new directions 3Users help software company morph in new directions 4State agencies propose venture capital center 2
(Date:8/20/2008)...genetic code of a simple saltwater creature could ...nes function in humans and other species. , A st...eaks down the genetic code of Trichoplax , a simp... in the world, even in the common household aquari...lax , genes that are also found in other animals -...
(Date:8/20/2008)...red tide algae, Karenia brevis, costs approximatel... coast of Florida alone. Scientists at the Georgia...can reduce the levels of the red tide,s toxicity t...tide,s toxicity to other algae as well. If scienti...xicity of red tide, they could reduce the vast amo...
(Date:8/20/2008)...arch Institute (NHGRI), part of the National Insti... million in grants to develop innovative sequencin... sequence a person,s DNA as a routine part of biom... to comprehensively sequence any person,s genome i...ge of personalized medicine where healthcare provi...
(Date:8/19/2008)...increase invasion of unwanted species, according t...anted species can completely overtake the reef and...easing the diversity of marine organisms on the re... rapid change in the dominant biota on a coral ree...ures. , The findings of the study, published in...
Breaking Biology News(10 mins):Genome of saltwater creature could aid understanding of gene grouping 2Biologists find diatom to reduce red tide's toxicity 2Biologists find diatom to reduce red tide's toxicity 3NHGRI seeks DNA sequencing technologies fit for routine laboratory and medical use 2NHGRI seeks DNA sequencing technologies fit for routine laboratory and medical use 3NHGRI seeks DNA sequencing technologies fit for routine laboratory and medical use 4NHGRI seeks DNA sequencing technologies fit for routine laboratory and medical use 5Shipwrecks on coral reefs harbor unwanted species 2David Pizzo Appointed Blue Cross and Blue Shield of Florida Market President West Florida 18149 1David Pizzo Appointed Blue Cross and Blue Shield of Florida Market President West Florida 18149 2Perrigo Company Announces Quarterly Dividend 18145 1Medco to Present at the Deutsche Bank 33rd Annual Health Care Conference 5028 1Medco to Present at the Deutsche Bank 33rd Annual Health Care Conference 5028 2CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts 1955 1CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts 1955 2
...culosis drug may be effective against not only mul...lso be the first compound to treat the latent stag...results today at the 2006 ASM Biodefense Research ...he lead has a very different mechanism of action f...losis. We have identified no cross resistance wit...
... than life ?big bones, big mysteries. So it,s a de...saurs may come from small ?very small ?remains. ,... University zoologist Peggy Ostrom. "We,ve shown t...eins can tell us about diseases, about where prehi...e and who they are related to." , Ostrom joins si...
...erpool is offering a new form of equine cataract r...e the sight of thousands of horses. , Professor ...f Equine Studies and Professor David Wong from the...que approach to cataract removal operations combin...w surgery is proving consistently successful in re...
...iversity of Minnesota Medical School have discover...ncurable degenerative brain disease affecting move...generative disease shown to be caused by mutations...rtant role in the maintaining the health of nerve ...lications as well--the gene was identified in an 1...
Other Biology News:Experimental TB drug effective against resistant and latent mycobacterium tuberculosis 2Next good dinosaur news likely to come from small packages 2Unique equine cataract surgery offered on routine basis 2U of MN researchers identify ataxia gene 2
...n that has been shown to help maintain the integri...anscription, in vitro RNA transcription, and in v... binds RNases in a 1:1 ratio. It inhibits a broad ...B, RNase C, and human placental RNase. RNA Safe do...
FastStart High Fidelity PCR System, dNTPack (Not available in US) from Roche Applied Science
RNase Inhibitor (Ribonuclease inhibitor) is a 50 kDa recombinant enzyme used to inhibit RNase activity. It does not contain DNase or endonuclease activity. , Inhibits RNase activity, preventing degr
HEPA Filtered Single Chamber Water Jacketed Incubator, CO2/O2 IR, 115V, 50/60 Hz from Thermo Scientific
Biology Products: